Abstract:Immunotherapy is a recent hotspot in lung cancer research. The ability of the immune system to recognize tumor cells as foreign is restricted through the expression of certain cell-surface molecules such as the major histocompatibility complex (MHC) molecules. The alteration in MHC class II antigens is an event that occurs frequently on primary and metastatic cancer. Therefore, we described the expression of MHC class II in lung cancer cell lines and patient tissues. We studied MHC II (DP, DQ, DR) (CR3/43, Abcam) protein expression in 55 non-small cell lung cancer (NSCLC) cell lines, 42 small cell lung cancer (SCLC) cell lines and 278 lung cancer patient tissues by immunohistochemistry (IHC). Seven (12.7%) NSCLC cell lines were positive for MHC class II. No SCLC cell lines were found to be MHC II positive. MHC class II was detected in 139 lung cancer samples from the Hirsch Lab. Twenty-one (31.3%) samples stained positive for MHC class II on tumor cells, and 38 (56.7%) had positive MHC class II expression on tumor infiltration lymphocytes (TILs) in NSCLC. There was no positive MHC class II staining on SCLC tumor cells. MHC class II on TILs in SCLC was significant lower than MHC II on TILs in NSCLC (P < 0.001). MHC class II was detected in 139 NSCLC tumor tissues from Medical University of Gdansk. Forty-two samples (30.2%) stained positive for MHC class II on tumor cells, and 55 (39.6%) had positive MHC class II expression on TILs in NSCLC. MHC class II on tumor cells was expressed less in non-adenocarcinoma compared to adenocarcinoma (P = 0.002). MHC class II on TILs had higher expression in stage I and II compared to stage III and IV NSCLC (P = 0.027). High expression of MHC class II on tumor cells was correlated with high expression of MHC class II on TILs (P = 0.023). Positive staining of MHC class II on TILs had longer RFS and OS than patients who were MHC class II negative on TILs (1.05 years 95% CI 0.57-1.55 vs. 2.98 years 95% CI 1.63-4.33, P = 0.028) (1.39 years, 95% CI 0.63-2.15 vs. 3.23 years 95% CI 2.62-3.84, P = 0.014). MHC class II was expressed in both NSCLC cell lines and tissues. However, MHC class II was absent in SCLC cell lines and tissue tumor cells. Loss of expression of MHC II on SCLC tumor cells may be a means of escaping anti-cancer immunity. MHC class II expression on TILs was correlated with good prognosis in NSCLC patients.

Expression of Human Leukocyte Antigen-I in Lung Cancer

Expression and clinical significance of human leukocyte antigen G in cervical cancer

Expression and Clinical Significance of Human Leucocyte Antigen Protein G in Colorectal Cancer

Expression of HLA-G in Cervical Cancer and Its Clinical Significance

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers

Expression of HLA Gene in Peripheral Blood Mononuclear Cell of Gastric Cancer Patients

Correlation between HLA-G and tumor immunity and its advances

Expression of HLA-G in Patients with Hepatocellular Carcinoma.

MHC Class II Expression in Lung Cancer

Up-regulation of HLA-G expression in cervical premalignant and malignant lesions.

Human leukocyte antigen-G and prognosis of liver transplantation in patients with hepatocellular carcinoma

HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis

Correlation between human leukocyte antigen G and gynecological neoplasms

[Research progress on HLA-G in non-small cell lung cancer]

[Clinical Implications of HLA-G Protein Expression in Acute Leukemia].

Expression of Human Leuocyte Antigen Ⅰ Antigen and Antigen Processing Machinery Components in Glioma Tissues and Their Correlation with Transporter Associated with Antigen Processing 2

Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer

Expression of HLA molecule in colorectal cancer tissue

Expression of Human Leukocyte Antigen-G and Its Prognosis Value for Liver Transplant Patients with Hepatocellular Carcinoma

Mhc Class Ii in Lung Cancer

[Association of Gene HLA-class I with Leukemia].